Improvement in clinical signs and cellular immunity of dogs with visceral leishmaniasis using the immunomodulator P-MAPA
Contribuinte(s) |
Universidade Estadual Paulista (UNESP) |
---|---|
Data(s) |
27/05/2014
27/05/2014
01/09/2013
|
Resumo |
This study investigated the immunotherapeutic potential of the protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride immuno-modulator (P-MAPA) on canine visceral leishmaniasis. Twenty mongrel dogs presenting clinical symptoms compatible with leishmaniasis and diagnosis confirmed by the detection of anti-leishmania antibodies were studied. Ten dogs received 15 doses of the immunomodulator (2.0mg/kg) intramuscularly, and 10 received saline as a placebo. Skin and peripheral blood samples were collected following administration of the immunomodulator. The groups were followed to observe for clinical signals of remission; parasite load in the skin biopsies using real-time PCR, the cytokines IL-2, IL-10 and IFN-γ in the supernatant of peripheral blood mononuclear cells stimulated in vitro with either total promastigote antigen or phytohemagglutinin measured by capture ELISA, and changes in CD4+ and CD8+ T cell subpopulations evaluated by flow cytometry. Comparison between the groups showed that treatment with the immunomodulator promoted improvement in clinical signs and a significant reduction in parasite load in the skin. In peripheral blood mononuclear cell cultures, supernatants showed a decrease in IL-10 levels and an increase in IL-2 and IFN-γ. An increase in CD8+ T cells was observed in peripheral blood. In addition, the in vitro leishmanicidal action of P-MAPA was investigated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and no leishmanicidal activity was detected. These findings suggest that P-MAPA has potential as an immunotherapeutic drug in canine visceral leishmaniasis, since it assists in reestablishing partial immunocompetence of infected dogs. © 2013 Elsevier B.V. |
Formato |
174-180 |
Identificador |
http://dx.doi.org/10.1016/j.actatropica.2013.04.005 Acta Tropica, v. 127, n. 3, p. 174-180, 2013. 0001-706X 1873-6254 http://hdl.handle.net/11449/76390 10.1016/j.actatropica.2013.04.005 WOS:000322294800004 2-s2.0-84878395018 |
Idioma(s) |
eng |
Relação |
Acta Tropica |
Direitos |
closedAccess |
Palavras-Chave | #CD4+ T #CD8+ T #Leishmania #P-MAPA #T lymphocytes #3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyltetrazolium bromide #antileishmanial agent #gamma interferon #interleukin 10 #interleukin 2 #Leishmania antibody #phytohemagglutinin #placebo #protein aggregate magnesium ammonium phospholinoleate palmitoleate anhydride #protozoal antigen #protozoal protein #protozoon antibody #unclassified drug #antibody #antigen #blood #canid #drug #immunity #leishmaniasis #parasite #symptom #animal tissue #antibody detection #blood sampling #CD4+ T lymphocyte #CD8+ T lymphocyte #cell culture #cell stimulation #cellular immunity #clinical feature #controlled study #cytokine production #dog disease #enzyme linked immunosorbent assay #flow cytometry #immunocompetence #immunomodulation #immunostimulation #immunotherapy #in vitro study #mononuclear cell #nonhuman #parasite load #promastigote #real time polymerase chain reaction #remission #skin biopsy #symptomatology #T lymphocyte subpopulation #visceral leishmaniasis #Canis familiaris |
Tipo |
info:eu-repo/semantics/article |